• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Deadly cancers show early, detectable differences from benign tumors

Bioengineer by Bioengineer
May 14, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

DURHAM, N.C. – Do metastatic cancer tumors "break bad" or are they "born bad"?

This question is an essential mystery in cancer early detection and treatment. Lacking a clear answer, patients are given the same aggressive therapies when small, abnormal clusters of cells are discovered early, even though they might well be harmless.

In a study publishing the week of May 14 in the Proceedings of the National Academy of Sciences, a research team co-led by scientists at Duke and the University of Southern California has found that in the colorectal tumors they examined, invasive cancers are born to be bad, and this tendency can potentially be identified at early diagnosis.

"We found evidence that benign and malignant tumors start differently, and that cell movement — an important feature of malignancy — manifests itself very early on during tumor growth," said lead author Marc D. Ryser, Ph.D., postdoctoral fellow in Duke's departments of Surgery and Mathematics.

"By testing screen-detected, small tumors for early cell movement as a sign of malignancy, it might be possible to identify which patients are likely to benefit from aggressive treatment," Ryser said.

Ryser and colleagues built on recent research showing that in a subset of human cancers, many key traits of the final tumor are already imprinted in the genome of the founding cell. As such, they reasoned, invasive tumors would start out with the ability to spread rather than developing that trait over time. That is, they are born to be bad.

The researchers analyzed 19 human colorectal tumors with genome sequencing technology and mathematical simulation models. They found signatures of early abnormal cell movement in the majority of the invasive samples — nine of 15. This propensity is required for tumors to spread, causing them to become deadly. Early abnormal cell movement was not apparent in the four benign tumors the researchers studied.

"The early growth of the final tumor largely depends on the drivers present in the founding cell," the authors wrote.

The study was small and the researchers acknowledged that verification in a larger sample is required, but the finding is a significant step toward establishing a test to distinguish between deadly and harmless growths.

"Thanks to improved screening technologies, we diagnose more and more small tumors," said senior author Darryl Shibata, M.D., professor in the Department of Pathology at Keck School of Medicine of USC. "Because treating a patient aggressively can cause them harm and side-effects, it is important to understand which of the small screen-detected tumors are relatively benign and slowly growing, and which ones are born to be bad."

###

In addition to Ryser and Shibata, study authors include Byung-Hoon Min, and Kimberly Siegmund.

The work received funding support from the National Institutes of Health (CA185016, CA196569, P30CA014089, K99CA207872), the National Science Foundation (DMS 1614838), and the Swiss National Science Foundation (P300P2-154583).

Media Contact

Samiha Khanna
[email protected]
919-419-5069
@DukeHealth

http://dukehealthnews.org

http://dx.doi.org/10.1073/pnas.1716552115

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Valencene Guards Against Benzo(a)pyrene Lung Cancer

August 5, 2025
blank

Impact of State-Level Insurance Expansion on Racial Disparities in Breast Density-Based Screening Eligibility

August 5, 2025

Comparing Pre-Surgery Therapies for Esophageal Cancer

August 5, 2025

TIGIT: Emerging Immune Checkpoint Target in Breast Cancer

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    72 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Stability and Refolding of Zika Virus EDIII Protein

Assessing Demirjian Method Reliability Among Forensic Experts

Malaria Rapid Test Accuracy in Young Burkina Faso Children

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.